Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

@article{Kirchheiner2002ImpactOC,
  title={Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.},
  author={Julia Kirchheiner and Steffen Bauer and Ingolf Meineke and Wolfgang Rohde and Verena Prang and Christian Meisel and Ivor Roots and J{\"u}rgen Brockm{\"o}ller},
  journal={Pharmacogenetics},
  year={2002},
  volume={12 2},
  pages={
          101-9
        }
}
Tolbutamide is known to be metabolized by cytochrome P450 2C9 (CYP2C9), and the effects of the CYP2C9 amino acid polymorphisms *2 (Arg144Cys) and *3 (Ile359Leu) could be important for drug treatment with tolbutamide and for use of tolbutamide as a CYP2C9 test drug. Tolbutamide pharmacokinetics and plasma insulin and glucose concentrations were studied in 23 healthy volunteers with all six combinations of the CYP2C9 alleles *1, *2 and *3, including two subjects with the combined CYP2C9*1/*1 and… Expand
Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
TLDR
The single CYP2C9*3 variant reduces the metabolism of losartan and its hypotensive effect and plasma MR, as well as urine MR, may be useful for phenotyping assays of CYP 2C9 activity. Expand
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
TLDR
The pharmacokinetic parameters of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP1C9 genetic SNP, which is a major cause of liver damage in healthy Chinese subjects. Expand
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
TLDR
The results suggested that the lower hydroxylation activity of glimepiride in the subject with type 2 diabetes and CYP2C9*1/*3 led to a marked elevation in the plasma concentrations of glimespiride and a stronger pharmacological effect of glIMEpiride. Expand
Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers
TLDR
The effect of CYP2C9 polymorphisms on nateglinide kinetics may cause a slightly increased risk for hypoglycaemia, which may become relevant in diabetic patients. Expand
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide
TLDR
A low dose of 125 mg tolbutamide can safely and accurately be used for CYP2C9 phenotyping and is proposed to determine tol butamide in plasma 24 h after drug intake. Expand
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
TLDR
CYP2C9 catalyses the biotransformation of the oral anticoagulants S-warfarin and R- and S-acenocoumarol and carriers of CYP 2C9*2 and *3 alleles had a lower metabolic capacity regarding phenprocoumon hydroxylation than those with CYP2C 9*1/*1. Expand
CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
TLDR
CYP2C9 genetic polymorphisms markedly affected the pharmacokinetics of irbesartan in this study sample and appear to be associated with the decreased metabolism of ir Besartan. Expand
Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus
TLDR
Patients with diabetes mellitus who are carriers of a CYP2C9*3 allele require lower doses of tolbutamide to regulate their serum glucose levels compared to patients with the wild‐type genotype. Expand
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
TLDR
It became evident that women on oral contraceptives (OCs) had slower oxidation of losartan than women without OCs, and CYP2C9 genotype and oral contraceptives both contribute to a large interindividual variation in CYP1C9 activity. Expand
Evaluation of the Relationship between Sex, Polymorphisms in CYP2C8 and CYP2C9, and Pharmacokinetics of Angiotensin Receptor Blockers
TLDR
It is suggested that genotypes for CYP2C9 and CYP1C8 are relevant to the pharmacokinetics of losartan and valsartan, respectively, but not the pharmacodynamics of candesartan or telmisartan. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
TLDR
Frequency of the two CYP2C9 variants in Turkish subjects was in a similar range as in other Caucasian populations, and a significant proportion of the interindividual variability in phenytoin trough levels is explained by the genotypes. Expand
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
TLDR
This study establishes that the Leu359 mutation is responsible for the phenytoin and glipizide/tolbutamide poor metabolizer phenotype. Expand
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
TLDR
Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates. Expand
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
TLDR
The present data suggest that the incidence of the Leu359 allelic variant of CYP2C9 may account for the occurrence of poor metabolizers of tolbutamide. Expand
Genetic analysis of the human cytochrome P450 CYP2C9 locus.
TLDR
Polymerase chain reaction-based assays are developed to distinguish all seven CYP2C9 cDNA sequences, and have determined their allele frequencies in the Caucasian population, allowing the prediction of CYP 2C9 phenotype, thus identifying those individuals who may exhibit different drug pharmacokinetics for CYP1C9 substrates. Expand
Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
TLDR
The tolbutamide urinary metabolic ratio effectively distinguishes tol butamide hydroxylase activity in “normal” subjects and in those converted to model phenotypically “poor” metabolizers by sulfaphenazole. Expand
A screening test for slow metabolisers of tolbutamide.
TLDR
A partial family study did not provide conclusive evidence of the inheritance of slow tolbutamide metabolism but the screening test should allow simple identification of slow metabolisers for further study. Expand
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.
TLDR
Tentative CYP genotype-based dose recommendations systematically calculated from published data are presented, and these doses will not be the optimal doses for each given individual, but should be more adequate than doses generally recommended for an average total population. Expand
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
TLDR
Comparisons for pharmacokinetic and toxicokinetic models of some of the clinically used drugs that are oxidized by CYP2C proteins in humans are provided and Immunoblotting analysis of human liver microsomes suggested that CYP 2C9 is a major component of the human CYP1C enzyme pool. Expand
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype
TLDR
The ratio of hydroxy- to carboxytolbutamide in subjects, and in other recent studies, suggests that some previous publications were inaccurate and their conclusions about the genetic control of tolbutamide metabolism were incorrect. Expand
...
1
2
3
...